Valuation Charles River Laboratories International, Inc.
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
NYSE
04:00:02 2026-08-20 pm EDT
|
5-day change | 1st Jan Change | ||
| 291.45 USD | +0.50% |
|
+3.62% | +46.10% |
| Aug. 20 | Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing | MT |
| Aug. 20 | Charles River, Medigen Partner on Multivalent Enterovirus Vaccine | MT |
Company Valuation: Charles River Laboratories International, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 18,941 | 11,138 | 12,252 | 9,520 | 10,023 | 13,913 | - | - |
| Change | - | -41.2% | 10% | -22.3% | 5.29% | 38.81% | - | - |
| Enterprise Value (EV) 1 | 21,366 | 13,616 | 14,622 | 11,565 | 11,946 | 16,026 | 15,544 | 15,151 |
| Change | - | -36.28% | 7.39% | -20.91% | 3.29% | 34.15% | -3% | -2.53% |
| P/E | 49.4x | 23.1x | 25.9x | 931x | -70x | 78x | 31.2x | 27.9x |
| PBR | 7.45x | 3.75x | 3.41x | 2.75x | 3.17x | 4.62x | 3.92x | 3.49x |
| PEG | - | 0.9x | -9.44x | -9.5x | 0x | -0x | 0x | 2.4x |
| Capitalization / Revenue | 5.35x | 2.8x | 2.97x | 2.35x | 2.5x | 3.56x | 3.48x | 3.31x |
| EV / Revenue | 6.04x | 3.42x | 3.54x | 2.86x | 2.98x | 4.1x | 3.89x | 3.6x |
| EV / EBITDA | 24.3x | 13.7x | 14.4x | 11.6x | 12.3x | 15.9x | 14.2x | 12.9x |
| EV / EBIT | 28.8x | 16.3x | 17.4x | 14.3x | 15x | 19.5x | 17x | 15.1x |
| EV / FCF | 40.2x | 46.2x | 40x | 23.1x | 23x | 50.8x | 25.5x | 31.7x |
| FCF Yield | 2.49% | 2.17% | 2.5% | 4.34% | 4.34% | 1.97% | 3.92% | 3.15% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 7.6 | 9.48 | 9.22 | 0.2 | -2.91 | 3.738 | 9.346 | 10.43 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 | 3,911 | 4,001 | 4,208 |
| EBITDA 1 | 879.5 | 990.9 | 1,013 | 996.1 | 971.5 | 1,008 | 1,093 | 1,174 |
| EBIT 1 | 742.1 | 834 | 838.8 | 805.9 | 793.9 | 821 | 912.3 | 1,001 |
| Net income 1 | 391 | 486.2 | 474.6 | 10.3 | -144.3 | 162.4 | 427.7 | 471.2 |
| Net Debt 1 | 2,425 | 2,477 | 2,370 | 2,046 | 1,923 | 2,112 | 1,631 | 1,237 |
| Reference price 2 | 375.34 | 218.92 | 238.84 | 186.16 | 203.66 | 291.45 | 291.45 | 291.45 |
| Nbr of stocks (in thousands) | 50,464 | 50,879 | 51,297 | 51,136 | 49,215 | 47,739 | - | - |
| Announcement Date | 2/16/22 | 2/22/23 | 2/14/24 | 2/19/25 | 2/18/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 77.97x | 4.1x | 15.89x | -.--% | 13.91B | |
| 34.4x | 6.13x | 18.24x | 0.93% | 51.22B | |
| -21.71x | 301.09x | -22.35x | -.--% | 45.38B | |
| 48.36x | 5.61x | 30.68x | -.--% | 41.97B | |
| 32.97x | 3.21x | 13.87x | -.--% | 42.15B | |
| 29.48x | 8.52x | 21.54x | 0.39% | 31.95B | |
| 34.84x | 5.71x | 25.97x | -.--% | 17.1B | |
| 24.28x | 2.11x | 9.12x | 1.11% | 14.76B | |
| 29.52x | 1.94x | 11.9x | -.--% | 13.45B | |
| Average | 32.23x | 37.60x | 13.87x | 0.27% | 30.21B | |
| Weighted average by Cap. | 27.86x | 54.56x | 12.65x | 0.28% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CRL Stock
- Valuation Charles River Laboratories International, Inc.
Select your edition
All financial news and data tailored to specific country editions
